Stock

Nektar Therapeutics NKTR

$70.45+1.59%

All stocks Create account to unlock

Overview

NKTR market data

Price History

NKTR price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for NKTR. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

4 captured

Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153 · Jul 22, 2026, 11:12 AM

Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029 · Jul 21, 2026, 11:10 AM

Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80 · May 11, 2026, 12:29 PM

8-K filing — NEKTAR THERAPEUTICS (NKTR) · May 8, 2026, 9:11 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock